News Author: Jennifer Smith Publish date: July 16, 2019
In a retrospective study of matched primary and metastases samples, PI3K signaling was associated with an increased risk of brain metastases, and C...
Article Author: Jennifer Smith Publish date: July 15, 2019
A systematic review suggests endoscopic treatment is appropriate for T1b esophageal cancers with a low risk of metastasis.
Article Author: Jennifer Smith Publish date: July 15, 2019
The University of Arizona (UA) Cancer Center has a new interim director, two hematologists have earned new positions at City of Hope, and an assist...
Article Author: Jennifer Smith Publish date: July 11, 2019
A systematic review suggests endoscopic treatment is appropriate for T1b esophageal cancers with a low risk of metastasis.
Video Author: Jennifer Smith Publish date: July 11, 2019
CHICAGO – In the COLUMBA trial, subcutaneous daratumumab proved noninferior to intravenous daratumumab in overall response rate and maximum trough ...
News Author: Jennifer Smith Publish date: July 9, 2019
Two-year survival rates were superior among patients who received CNS-intensive therapy.
Article Author: Jennifer Smith Publish date: July 1, 2019
Dr. George J. Broze, who is known for his research on hemostasis and the relationship between coagulation and inflammation, died following a heart ...
News Author: Jennifer Smith Publish date: June 26, 2019
Tumor-associated CD8+ T cells responded to 86% of neoantigens tested and recognized 68% of neoepitopes tested in samples from pediatric ALL patient...
News Author: Jennifer Smith Publish date: June 21, 2019
Preclinical research suggests TCF4 is an oncogene in ABC-like DLBCL and can be targeted via BET inhibition.
News Author: Jennifer Smith Publish date: June 17, 2019
CHICAGO – Durvalumab plus R-CHOP induction produced a complete response rate of 54%.
Article Author: Jennifer Smith Publish date: June 17, 2019
Dr. John D. Carpten and Dr. Roderic I. Pettigrew have joined the Stand Up To Cancer scientific advisory committee. And Fox Chase Cancer Center in P...
News Author: Jennifer Smith Publish date: June 14, 2019
CHICAGO – R2 produced responses in patients who were refractory to rituximab or both lenalidomide and rituximab at baseline.
News Author: Jennifer Smith Publish date: June 12, 2019
CHICAGO – Patients who received isatuximab plus pomalidomide and dexamethasone had a median progression-free survival of 11.53 months.
News Author: Jennifer Smith Publish date: June 12, 2019
CHICAGO – Results with daratumumab plus bortezomib, thalidomide, and dexamethasone are the “best ever reported in the setting of stem cell transpla...
News Author: Jennifer Smith Publish date: June 12, 2019
CHICAGO – There was no difference in overall or progression-free survival between patients receiving ipilimumab plus nivolumab and those receiving ...
